CreditRiskMonitor is a financial risk analysis and news service for credit, supply chain and financial professionals.  Our strength in coverage spans 58,000 global public companies, totaling about $70 trillion in corporate revenue.  We also offer solutions that can help ease private company financial risk assessment.  Leading corporations around the world – including more than 35% of the Fortune 1000, plus thousands more worldwide – rely on us to help them stay ahead of financial risk quickly, accurately and cost-effectively. 

A partial report preview for BioCryst Pharmaceuticals Inc is shown below.  Where indicated by "Yes," CreditRiskMonitor contains this information in its extensive database.  To get access to the full report and learn more about CreditRiskMonitor's robust financial risk analysis and timely news service, request a personalized demo and free trial today.

If you are already a subscriber and want to access the full report, click here.

BioCryst Pharmaceuticals Inc
4505 Emperor Blvd Ste 200
Phone: (302) 636-5400p:302 636-5400 DURHAM, NC  27703-8457  United States Ticker: BCRXBCRX
Business Summary
BioCryst Pharmaceuticals, Inc. is a biotechnology company focused on developing and commercializing medicines for hereditary angioedema (HAE) and other rare diseases. Its marketed products include oral, once-daily ORLADEYO for the prevention of hereditary angioedema (HAE) attacks and RAPIVAB (peramivir injection) for the treatment of acute uncomplicated influenza in the United States. Its other products and product candidates include BCX10013, RAPIACTA (peramivir injection), PERAMIFLU (peramivir injection), and early-stage discovery programs. BCX10013, is a potent and specific Factor D inhibitor. RAPIACTA focuses on uncomplicated seasonal influenza. The RAPIVAB (peramivir injection) is approved in the United States for the treatment of acute uncomplicated influenza for patients six months and older. Its portfolio also includes navenibart, which is a late-stage, long-acting plasma kallikrein inhibitor. It has also obtained an early-stage program for atopic dermatitis, STAR0310.
(Source: 6-K)

Scores and Ratings
FRISK®
Score		 Z''
Score		 PAYCE®
Score		 DBT
Index		 Moody's
Rating		 Fitch
Rating		 DBRS
Rating
YesYes-Yes---

Financials, News and Filings
Latest
Statement		 Last
Audit
News		 SEC
Filings		 Bankruptcy
Filings		 Suit &
Judgment
Filings		 Tax
Lien
Filings
9/30/202512/31/2024YesYes--Yes

Industries
SIC Code Description
2836 Biological products, except diagnostic substances
2834 Pharmaceutical preparations
8731 Commercial physical and biological research

Officers and Directors

Title
Name
Age		 Title
Date		 Start
Date
Independent Chairman of the Board Nancy J.Hutson 75 3/31/2023 1/20/2012
President, Chief Executive Officer, Director Charles K.Gayer 54 1/1/2026 1/15/2020
Chief Financial Officer, Head of Corporate Development BabarGhias 7/7/2025 7/7/2025
5 additional Officers and Directors records available in full report.

Subsidiaries
Business Name Address City State/Province Country
Astria Therapeutics Inc 22 Boston Wharf Road, 10Th Floor BOSTON MA United States

Business Names
Business Name
Astria Therapeutics Inc
BCRX
BioCryst Canada, ULC
11 additional Business Names available in full report.

General Information
Number of Employees: 580 (As of 12/31/2024)
Outstanding Shares: 248,039,061 (As of 1/23/2026)
Shareholders: 147
Stock Exchange: NASD
Federal Tax Id: 621413174
Fax Number: (302) 636-5454
Email Address: info@biocryst.com


Copyright © 2026 CreditRiskMonitor.com (Ticker: CRMZ). All rights reserved.     
By using this website, you accept the Terms of Use Agreement.
Tuesday, February 3, 2026